首页> 外文期刊>Cardiology >The effect of atorvastatin treatment on lipid profile and adhesion molecule levels in hypercholesterolemic patients: relation to low-density lipoprotein receptor gene polymorphism.
【24h】

The effect of atorvastatin treatment on lipid profile and adhesion molecule levels in hypercholesterolemic patients: relation to low-density lipoprotein receptor gene polymorphism.

机译:阿托伐他汀治疗对高胆固醇血症患者血脂和粘附分子水平的影响:与低密度脂蛋白受体基因多态性的关系。

获取原文
获取原文并翻译 | 示例
           

摘要

Inflammation has been indicated to play a major role in the development of atherosclerosis. The beneficial effect of statins has been suggested to be related to their anti-inflammatory properties. We have studied plasma levels of soluble adhesion molecules in patients with hypercholesterolemia before and after 3 months of treatment with atorvastatin and evaluated possible relations to the mutations in low-density lipoprotein receptor (LDLR) gene. In patients with no LDLR gene polymorphism (group A), lower baseline levels of total cholesterol and LDL cholesterol were found than in patients with LDLR gene polymorphism (group B). The soluble adhesion molecules sICAM-1, sE-selectin and sP-selectin, but not sVCAM-1 and sL-selectin, were higher in group B than in group A. sICAM-1 levels decreased in group A by 7% (p = 0.007) and in group B by 21% (p = 0.039), whereas levels of sVCAM-1 decreased in group A by 12% (p = 0.001) and in group B patients by 19% (p = 0.039). Atorvastatin did not change sE-selectin nor sP-selectin levels in group A. However, in group B, the treatment reduced E-selectin and sP-selectin levels by 39% (p = 0.007) and 24% (p = 0.007), respectively. Atorvastatin attenuates the inflammatory reaction in hypercholesterolemic patients, but in patients with LDLR gene polymorphism, this effect is more profound.
机译:已经表明炎症在动脉粥样硬化的发展中起主要作用。他汀类药物的有益作用被认为与其抗炎特性有关。我们已经研究了高胆固醇血症患者在使用阿托伐他汀治疗3个月之前和之后的血浆可溶性粘附分子水平,并评估了其与低密度脂蛋白受体(LDLR)基因突变的可能关系。没有LDLR基因多态性的患者(A组)发现总胆固醇和LDL胆固醇的基线水平低于LDLR基因多态性的患者(B组)。 B组的可溶性粘附分子sICAM-1,sE-选择素和sP-选择素高于sVCAM-1和sL-选择素,而B组则不高于A组。A组sICAM-1水平降低了7%(p = 0.007)和B组降低了21%(p = 0.039),而A组sVCAM-1的水平降低了12%(p = 0.001),而B组患者的sVCAM-1水平降低了19%(p = 0.039)。阿托伐他汀没有改变A组的sE-选择素和sP-选择素水平。但是,在B组中,治疗使E-选择素和sP-选择素水平降低了39%(p = 0.007)和24%(p = 0.007),分别。阿托伐他汀可减轻高胆固醇血症患者的炎症反应,但在具有LDLR基因多态性的患者中,这种作用更为明显。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号